Phenotypes associated with this allele
immune system
N |
• normal numbers of mature B cells including follicular and marginal zone B cells are produced
• spleens contain well-organized lymphoid architecture with normal follicles and distinct marginal zone
|
cellular
|
• 1-2 days after crosslinking with BCR, there are less apoptotic cells than in purified wild-type B cell cultures
|
|
• 1-2 days after crosslinking with BCR, there are more cells is S phase than in wild-type B cell cultures
|
immune system
|
• B cell numbers are increased in spleens (130 x 106) compared to wild-type (56 x 106)
|
|
• B cell hyperplasia is observed, with a significantly expanded population of marginal zone B cells
|
|
• cells on average have a longer lifespan than wild-type B cells
|
|
• 1-2 days after crosslinking with BCR, there are less apoptotic cells than in purified wild-type B cell cultures
|
hematopoietic system
|
• B cell numbers are increased in spleens (130 x 106) compared to wild-type (56 x 106)
|
|
• B cell hyperplasia is observed, with a significantly expanded population of marginal zone B cells
|
|
• cells on average have a longer lifespan than wild-type B cells
|
|
• 1-2 days after crosslinking with BCR, there are less apoptotic cells than in purified wild-type B cell cultures
|
immune system
|
• mice exhibit a very limited rescue of BCR negative B cells in several lymphoid organs compared with Igh-Jtm1Cgn/Ightm4Cgn Tg(Cr2-cre)3Cgn mice
|
hematopoietic system
|
• mice exhibit a very limited rescue of BCR negative B cells in several lymphoid organs compared with Igh-Jtm1Cgn/Ightm4Cgn Tg(Cr2-cre)3Cgn mice
|
hematopoietic system
|
• mice show some reduction in the germinal center B cell fraction at day 10 after primary and secondary immunization
|
|
• hyperplasia of B cells in the spleen and bone marrow at 550-600 days
|
|
• hyperplasia of plasma cells in the spleen and bone marrow at 550-600 days
• clonal or oligoclonal plasma cell expansions
|
|
• large numbers of cells expressing intracellular Ig and the plasma cell marker CD138 are seen in spleens
|
|
• enlarged spleens in mice 550-600 days of age
|
immune system
|
• mice show some reduction in the germinal center B cell fraction at day 10 after primary and secondary immunization
|
|
• hyperplasia of B cells in the spleen and bone marrow at 550-600 days
|
|
• hyperplasia of plasma cells in the spleen and bone marrow at 550-600 days
• clonal or oligoclonal plasma cell expansions
|
|
• large numbers of cells expressing intracellular Ig and the plasma cell marker CD138 are seen in spleens
|
|
• enlarged spleens in mice 550-600 days of age
|
growth/size/body
|
• enlarged spleens in mice 550-600 days of age
|
hematopoietic system
|
• plasma cell formation is severely impeded 10 days after primary and secondary immunization
|
|
• mice show increased numbers of germinal center B cells at day 10 after primary immunizations
|
|
• small, but significant, increase of the fraction of germinal center B cells in the S and G2 phases of the cell cycle
|
|
• reduction in total as well as sheep red blood cell-specific IgG1, but not IgM, antibodies 10 days after primary and secondary immunization
|
immune system
|
• plasma cell formation is severely impeded 10 days after primary and secondary immunization
|
|
• mice show increased numbers of germinal center B cells at day 10 after primary immunizations
|
|
• small, but significant, increase of the fraction of germinal center B cells in the S and G2 phases of the cell cycle
|
|
• reduction in total as well as sheep red blood cell-specific IgG1, but not IgM, antibodies 10 days after primary and secondary immunization
|
mortality/aging
|
• shortened survival, with 40% survival at around 500 days of age
|
neoplasm
|
• mice succumb to a B cell-derived lymphoproliferative disease affecting spleen and lymph nodes, resembling human diffuse large B cell lymphoma
• mice develop clonal lymphomas consistent with activated B cell-diffuse large B cell lymphoma
|
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd79atm1(cre)Reth mutation
(3 available);
any
Cd79a mutation
(22 available)
Gt(ROSA)26Sortm4(Ikbkb)Rsky mutation
(2 available);
any
Gt(ROSA)26Sor mutation
(942 available)
Sh3kbp1tm1Kuro mutation
(0 available);
any
Sh3kbp1 mutation
(6 available)
|
|
|
immune system
N |
• T cell independent type II antibody responses are restored
|
|
• B-1a cell development continues to be defective
|
hematopoietic system
|
• B-1a cell development continues to be defective
|